Comparison · NCT01908426-61df249e
Cabozantinib (XL184) vs Placebo: Objective Response Rate (ORR)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cabozantinib (XL184) vs Placebo: Objective Response Rate (ORR). Trial comparisons, record NCT01908426-61df249e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01908426-61df249e
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0383 | 0.0244 | 0.0597 | wilson | |
| Risk in group 2 | 0.00422 | 0.000745 | 0.0235 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0341 | 0.0103 | 0.0558 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 9.08 | 1.22 | 67.6 | log | |
| Odds ratio, group 1 over group 2 | 9.4 | 1.25 | 70.8 | log | |
| Number needed to treat, for one more participant with the outcome on Cabozantinib (XL184) than on Placebo | 29.3 | 17.9 | 97.3 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cabozantinib (XL184) | Cabozantinib (XL184) 60 mg tablet once daily~Cabozantinib tablets | 18 | 470 | OG000 |
| Group 2 | Placebo | Oral cabozantinib-matched placebo tablet once daily~Placebo tablets | 1 | 237 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Objective Response Rate (ORR)
- Description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
- Time frame
- ORR is measured by radiologic assessment every 8 weeks after randomization until disease progression or discontinuation of study treatment (up to 45 months)
- Population
- The analysis of ORR was performed in the ITT population (all randomized: 470 cabozantinib, 237 placebo) based upon response determined by Investigator per RECIST 1.1
Source ClinicalTrials.gov
Trial
- Title
- Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
- NCT number
- NCT01908426
- Phases
- PHASE3
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Cabozantinib tablets, Placebo tablets
- Lead sponsor
- Exelixis
- Results first posted
- 2019-03-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01908426?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01908426-61df249e